Sidebar

04
Mon, Jul

UK charity (CRT) to test experimental Astra cancer drug AZD-3965 that targets cell metabolism (MCT-1) - Reuters (article link)

Typography
  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

(Reuters) - AstraZeneca has agreed a deal with the commercial arm of a British charity to take an experimental cancer drug into early clinical trials.
- The work will be carried out by the charity's development and commercialization arm, Cancer Research Technology (CRT).

AZD-3965, is one of a new class of cancer metabolism drugs and targets the monocarboxylate transporter 1 (MCT-1) which is essential in cell metabolism.
- The idea is that by blocking MCT-1 the drug could limit cancer cells' ability to generate energy, reducing their ability to survive.

AstraZeneca signed a previous agreement with CRT in February for a three-year alliance to work on projects aiming to exploit the fact cancer cells use energy differently to normal cells.


UK charity to test experimental Astra cancer drug
http://www.reuters.com/article/idUSTRE68B2T120100912

(Reuters) - AstraZeneca has agreed a deal with the commercial arm of a British charity to take an experimental cancer drug into early clinical trials.